intoplicine
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1997 (NCT00003713)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNA topoisomerase IIINHIBITOR
DNA topoisomerase II inhibitor
- Topoisomerase IINHIBITOR
Topoisomerase I inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cnc(NCCCN(C)C)c2c1[nH]c1ccc3cc(O)ccc3c12- Mol. weight
- 348.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1908351 ↗
Also known as
- 11-(3-dimethylaminopropylamino)-3-hydroxy-8-methyl-7h-benzo(e)pyrido(4,3-b)indole dimethanesulfonate
- 7h-benzo(e)pyrido(4,3-b)indol-3-ol, 11-((3-(dimethylamino)propyl)amino)-8-methyl-
- intoplicin
- intoplicine
- intoplicine
- intoplicine
- intoplicine
- intoplicine
- intoplicine
- intoplicine
- nsc d645008
- rp-60475
- rp-60475
- rp-60475
- rp60475f
- rp 60475f
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003713 | Phase 1 | Aug 1, 1997 | Genzyme |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genzyme | For profit | 1 | 1 | 1 | 1997 |
1 organizations
Page 1 / 1